Helena Edlund

Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration

Helena Edlund, Casper Steenholdt, Mark Ainsworth et al. · The AAPS Journal · 2016 · 31 citations

Pharmacy, Immunology, Pharmacokinetics +15

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies

Helena Edlund, Sun Ku Lee, Marilee Andrew et al. · Clinical Pharmacokinetics · 2018 · 19 citations

Medicine, Pharmacokinetics, Pharmacology +11

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies

Helena Edlund, Núria Buil‐Bruna, Karthick Vishwanathan et al. · British Journal of Clinical Pharmacology · 2021 · 15 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach

Helena Edlund, Francesco Bellanti, Huan Liu et al. · British Journal of Clinical Pharmacology · 2021 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15